CELC
HEALTHCARECelcuity Inc
$139.44-2.25 (-1.59%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CELC Today?
No stock-specific AI insight has been generated for CELC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.51$151.02
$139.44
Fundamentals
Market Cap$6.7B
P/E Ratio—
EPS$-3.79
Dividend Yield—
Dividend / Share—
ROE-1.6%
Profit Margin—
Debt / Equity—
Trading
Volume802K
Avg Volume (10D)—
Shares Outstanding48.3M
CELC News
20 articles- Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference CallYahoo Finance·May 7, 2026
- Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?Yahoo Finance·May 6, 2026
- Top Midday GainersYahoo Finance·May 4, 2026
- AMD downgraded, Airbnb upgraded: Wall Street's top analyst callsYahoo Finance·May 4, 2026
- Celcuity strengthens case for ASCO-spotlighted breast cancer drugBiopharmadive·May 4, 2026
- Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant CohortYahoo Finance·May 1, 2026
- Why Celcuity Stock Popped on MondayThe Motley Fool·Apr 27, 2026
- Celcuity Inc. (CELC): Likely Leader in Next Generation of Breast Cancer TreatmentsYahoo Finance·Apr 27, 2026
- Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price RallyYahoo Finance·Apr 6, 2026
- Why Celcuity Stock Popped TodayThe Motley Fool·Mar 27, 2026
- Celcuity Inc. Q4 2025 Earnings Call SummaryMoby·Mar 26, 2026
- Celcuity Inc (CELC) Q4 2025 Earnings Call Highlights: Navigating Losses Amidst Promising Drug ...Yahoo Finance·Mar 26, 2026
- Celcuity Q4 Earnings Call HighlightsMarketbeat·Mar 25, 2026
- Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 25, 2026
- Stocks Rebound Pre-Bell as US Reportedly Sends Peace Plan to IranYahoo Finance·Mar 25, 2026
- Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?Motley Fool·Mar 20, 2026
- What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For ShareholdersYahoo Finance·Mar 15, 2026
- Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink ConferenceMarketbeat·Mar 14, 2026
- Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer DrugMotley Fool·Mar 13, 2026
- Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC FilingMotley Fool·Mar 10, 2026
All 20 articles loaded
Price Data
Open$140.55
Previous Close$141.69
Day High$142.61
Day Low$133.95
52 Week High$151.02
52 Week Low$9.51
52-Week Range
$9.51$151.02
$139.44
Fundamentals
Market Cap$6.7B
P/E Ratio—
EPS$-3.79
Dividend Yield—
Dividend / Share—
ROE-1.6%
Profit Margin—
Debt / Equity—
Trading
Volume802K
Avg Volume (10D)—
Shares Outstanding48.3M
About Celcuity Inc
Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in Minneapolis, Minnesota.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—